Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation

Size: px
Start display at page:

Download "Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation"

Transcription

1 Original Article Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation United European Gastroenterology Journal 2016, Vol. 4(1) 77 83! Author(s) 2016 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / ueg.sagepub.com Rinkesh Kumar Bansal, Mandhir Kumar, Piyush Ranjan Munish Sachdeva and Ashish Kumar Abstract Background and objectives: Patients with liver cirrhosis are more prone to develop reduced bone mineral density (BMD), i.e. hepatic osteodystrophy (HOD). There are few data on the prevalence of HOD in the Indian population and its treatment. We aimed to determine the prevalence of HOD, factors associated with it and the impact of bisphosphonates on BMD in patients with liver cirrhosis. Patients and methods: Consecutive patients with liver cirrhosis admitted at Sir Ganga Ram Hospital, New Delhi, between August 2012 and July 2013 were enrolled. Patients with chronic kidney disease, hyperparathyroidism and those on steroids were excluded. BMD was measured by dual-energy X-ray absorptiometry (DEXA) at the lumbar spine and femoral neck. Osteopenia and osteoporosis were defined according to WHO criteria. Ibandronic acid 150 mg per day orally for six months was given to patients with osteoporosis and DEXA scan repeated. Results: A total of 215 patients (males 179, 83%) with a mean age of years were enrolled in this study. Prevalence of HOD was found to be 66% (142/215). On multivariate analysis BMI, TLC, total serum bilirubin and transient elastography values were found to be independently associated with HOD. All the patients with osteoporosis (n ¼ 47) were treated with ibandronic acid as per protocol. Treated patients had significant improvement in DEXA scans after six months as compared to baseline. Conclusions: HOD was seen in two-thirds of patients with liver cirrhosis. Higher liver stiffness as determined by transient elastography is significantly associated with HOD. Severity scores of liver disease (CTP and MELD) and etiology of liver cirrhosis did not determine HOD. Ibandronic acid is a safe drug that showed significant improvement in BMD in patients with liver disease along with osteoporosis. Keywords Hepatic osteodystrophy, osteoporosis in cirrhosis, bisphosphonates in cirrhosis, bone disease in cirrhosis, fractures in liver cirrhosis Received: 6 January 2015; accepted: 1 April 2015 Introduction Hepatic osteodystrophy (HOD) is the term coined to describe bone disease in patients with chronic liver disease. 1 It includes both osteopenia and osteoporosis. Dual-energy X-ray absorptiometry (DEXA) scan is the gold standard for diagnosing HOD. HOD is a common but overlooked problem in patients with liver cirrhosis. It is more commonly seen in cholestatic liver disease but has also been reported in non-cholestatic liver diseases. Overall prevalence of HOD ranges from 13% to 70%. 1,2 The exact prevalence of HOD in non-cholestatic diseases has not been studied adequately. Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India Corresponding author: Piyush Ranjan, Department of Gastroenterology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India, piyushranjan70@gmail.com

2 78 United European Gastroenterology Journal 4(1) The predisposing factors for HOD in liver cirrhosis patients have not been studied adequately. There are few data on the relation of severity of liver disease (Child-Turcotte-Pugh (CTP) or MELD score) and portal hypertension with HOD. Treatment of HOD in non-choleastatic liver disease has been inadequately studied. The aims of this study were (i) to determine the prevalence of HOD in non-cholestatic chronic liver disease, (ii) to assess the predictive factors of HOD, (iii) to study the relation of severity of liver disease with HOD and (iv) to study the impact of bisphosphonates on bone mineral density (BMD). Patients and methods Patients In this prospective study, all consecutive patients with liver cirrhosis attending the department of Gastroenterology and Hepatology, Sir Ganga Ram Hospital, New Delhi, between August 2012 and July 2013 were included. Liver cirrhosis was diagnosed on the basis of clinical, biochemical and radiological features. Patients age <18 years and >70 years, those with cholestatic liver disease, chronic renal failure, prolonged steroid use (more than three months), pregnancy, post-menopausal women, those on immunosuppressive therapy, with primary hyperparathyroidism, Cushing s syndrome, malignancy (except hepatocellular carcinoma (HCC)) and human immunodeficiency virus (HIV) co-infection were excluded. Baseline work-up All patients underwent a detailed clinical assessment and relevant laboratory investigations. The investigations included a complete hemogram, renal function tests and liver function tests (LFTs) including prothrombin time (international normalized ratio (INR)). Etiological work-up for liver cirrhosis included HBsAg, anti-hepatitis C virus (HCV) antibody, antinuclear antibodies (ANA), anti-smooth muscle antibodies (ASMA), anti-liver-kidney-microsomal (LKM) antibodies, serum ceruloplasmin, and iron studies. Ultrasound was performed in all patients and triphasic computed tomography (CT) of the abdomen was conducted when there was suspicion of HCC. Upper gastrointestinal (GI) endoscopy and FibroScan were performed in all patients. Serum calcium, phosphate, 25-hydroxyvitamin D (25-OH D), fasting thyroid profile and intact parathyroid hormone (PTH) levels were estimated in all patients. Sex hormone (free testosterone in males, estradiol and luteinizing hormone in females) were also tested. BMD was measured by DEXA scan at two sites, i.e. the lumbar spine and femoral neck using a GE Lunar prodigy. Encore TM 2008 Software, GE Health Care system, version 12.20, was used to compute the BMD in g/cm 2. HOD was defined according to World Health Organization (WHO) criteria. T score was defined as number of standard deviations (SD) from mean BMD values of healthy young adults. Normal BMD was a T- score between þ 2.5 and 1. Osteopenia was defined as a T score between 1 and 2.5 and osteoporosis was defined as a T score < 2.5. Patients were divided into three groups on the basis of BMD: Group A had normal BMD, Group B had osteopenia and Group C had osteoporosis. All the parameters among these three groups were compared and analyzed. Treatment All patients with osteopenia and osteoporosis received calcium and vitamin D supplementation. Calcium was given in a dosage of 1000 mg. Vitamin D was given in a dosage of 60,000 IU per week. Ibandronic acid (second-generation bisphosphonate) was given to the patients with osteoporosis in a dosage of 150 mg per orally once a month for six months. Follow-up All patients with osteoporosis were followed-up for a period of six months. Those patients who completed six months of ibandronic acid were categorized as the treatment group. A repeat DEXA scan was performed along with relevant laboratory parameters in patients who received treatment after six months and these parameters were compared with baseline values. Any adverse effects of ibandronic acid were also recorded. Statistical analysis Statistical analysis was carried out using the Statistical Package for Social Sciences (SPSS, version 17.0). Normality of data was checked by measurement of skewness and the Kolmogorov-Smirnov test for normality. All quantitative variables are expressed as mean (SD) for normally distributed data and median (interquartile range (IQR)) if the data were skewed. Normally distributed data means were compared using a one-way analysis of variance (ANOVA), and if the F value was significant and variance was homogeneous, the Bonferroni multiple comparison test was

3 Bansal et al. 79 used to assess the differences between the individual groups; otherwise, Tamhane s T2 test was used. The Kruskal-Wallis test was used for those variables that were not normally distributed and further comparisons were performed using the Mann-Whitney U test. Multivariate logistic regression analysis was conducted using a stepwise method to find independent factors associated with osteopenia and osteoporosis. Qualitative or categorical variables were described as proportions. Proportions were compared by use of the chi-square test or Fisher s exact test, whichever was applicable. For all statistical tests, a p value less than 0.05 was taken to indicate a significant difference. Results Baseline characteristics A total of 215 patients with liver cirrhosis were included in this study. The mean age of the study group was years and there were 179 males and 36 females. The etiology of liver cirrhosis was alcohol in 98 patients (45.6%), non-alcoholic steatohepatitis (NASH) in 52 (24.2%), hepatitis B virus (HBV) in 21 (9.8%), HCV in 14 (6.5%), autoimmune in one and cardiac cirrhosis in one. In 28 (13%) patients no cause was found after defined work-up and they were termed cryptogenic (Table 1). The mean CTP of the entire group was , out of whom 7% (15) patients were in Child Class A; 41% (88) patients were in Child Class B; and 52% (112) patients were in Child Class C. The mean Model for End-Stage Liver Disease (MELD) score of the study population was Ascites were present in 81.4% (n ¼ 175) of the patients. Out of total patients with ascites, mild ascites were present in 41.7% (n ¼ 73), moderate ascites were present in 19.4% (n ¼ 34) and gross ascites were present in 38.9% (n ¼ 68). Esophageal varices were present in 83.7% (n ¼ 180), the majority of whom (63.3%) (n ¼ 114) had small varices while the rest (36.6%) had large varices. Prevalence and associations of HOD Prevalence of HOD as defined by T score at the lumbar vertebra was 66% (n ¼ 142) and at the femoral neck it was 44% (n ¼ 95). All the patients who showed HOD at the femoral neck also had HOD at the lumbar vertebra. Patients were divided into three groups based on BMD results: those with normal bone density, group A (n ¼ 73, 34%), those with osteopenia, group B (n ¼ 95, 44.2%) and those with osteoporosis, group C (n ¼ 47, 21.8%). All baseline characters and laboratory parameters were compared among these three groups. Table 1. Baseline clinical parameters of patients. PARAMETERS (n ¼ 215) Age in years Gender (male/female) 182 (84.7%)/33 (15.3%) ETIOLOGY 98 (45.6%) ALD 52 (24.8%) NASH 28 (13%) Cryptogenic 21 (9.8%) HBV 14 (6.5%) HCV 1(0.5%) Autoimmune 1(0.5%) Cardiac Child-Pugh Class A/B/C 15/88/112 (7%/41%/52%) Mean CTP score Mean MELD score ALD: alcoholic liver disease; NASH: non-alcoholic steatohepatitis; HBV: hepatitis B virus; HCV: hepatitis C virus; CTP: Child-Turcotte-Pugh; MELD: Model for End-Stage Liver Disease. On univariate analysis, using the Mann-Whitney U test, weight, body mass index (BMI), serum total bilirubin, serum glutamic pyruvic transaminase (SGPT), total leukocyte count (TLC), platelet counts, serum creatinine and FibroScan value were statistically different among group A, B and C (Table 2). Using multivariate logistic regression analysis with a stepwise method FibroScan, BMI, TLC and serum total bilirubin, were found to be statistically significant in these three groups (Table 3). There was no difference in age and gender distribution, calcium, phosphate, vitamin D, thyroid-stimulating hormone (TSH) and PTH among all these groups. The relation between etiology of liver cirrhosis and HOD was studied but there was no statistical impact of particular etiology on BMD (Table 4). The relation between severity of liver disease and HOD was studied using Child score, MELD score and FibroScan. In Child A cirrhosis, seven (46.66%) had normal BMD, five (33.33) had osteopenia and three (20%) had osteoporosis. In Child B cirrhosis, 26 (29.5%) had normal BMD, 39 (44.3%) had osteopenia and 23 (26.1%) had osteoporosis. In Child C liver cirrhosis, 41 (35.7%) had normal BMD, 51 (45.5%) had osteopenia and 21 (18.75%) had osteoporosis. The difference in prevalence of osteopenia and osteoporosis among various Child groups was not significant statistically (p ¼ 0.512) (Figure 1). The MELD score of Group A was , Group B was and Group C was Using the Mann-Whitney test, there was

4 80 United European Gastroenterology Journal 4(1) Table 2. Univariate analysis of baseline demographic and laboratory parameters of patients. Normal bone density (Group A) (n ¼ 73) Osteopenia (Group B) (n ¼ 95) Osteoporosis (Group C) (n ¼ 47) p value Age (year) Weight (kg) Height (cm) BMI (kg/m 2 ) a Hemoglobin (g/dl) a TLC (thous/ml) 8 ( ) 7.7 ( ) 5.6 ( ) a Platelets count (thous/ml) 94 ( ) 85 (55 130) 75 (57 105) a Creatinine (mg/dl) 1.07 ( ) 1.07 ( ) 0.91 ( ) a Bilirubin (mg/dl) 2.7 ( ) 3.7 (1.6 12) 2.1 ( ) a SGOT (IU/l) 66 (48 135) 73 (43 107) 52 (42 81) SGPT (IU/l) 37 ( ) 34 (24 56) 28 (21 34) a Calcium (mg/dl) Phosphorus (mg/dl) PTH (pg/ml) 36.91( ) ( ) ( ) Vit D (ng/ml) 7.24 ( ) 7.52 ( ) 7.11 ( ) Albumin (g/dl) 2.5 (2.2 3) 2.5 ( ) 2.5 ( ) INR 1.5 ( ) 1.57 ( ) 1.55 ( ) FibroScan (kpa) 40 (12 75) 51 ( ) 62 ( ) <0.001 a a Significant p value. BMI: body mass index; TLC: total leukocyte count; SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvic transaminase; PTH: parathyroid hormone; Vit: vitamin; INR: international normalized ratio. Table 3. Predictive factors for osteoporosis as compared to normal BMD on multivariate analysis. Sig. Odds ratio 95% CI BMI (kg/m 2 ) a TLC (thous/ml) a Bilirubin (mg/dl) a FibroScan (kpa) <0.001 a a Significant p value. BMD: bone mineral density; BMI: body mass index; TLC: total leukocyte count; CI: confidence interval. no statistical association of MELD score with HOD (p ¼ 0.112) (Figure 2). Mean FibroScan value was 40 kilo pascal (kpa) in Group A, 51 kpa in Group B and 62 kpa in Group C. FibroScan in patients with osteoporosis and osteopenia were significantly higher as compared to those with normal BMD (Groups A and B p < 0.001, Groups A and C p < 0.001). Patients with osteoporosis had higher FibroScan values as compared to those with osteopenia (Group B and C p ¼ 0.001) (Figure 3). To test the usefulness of FibroScan for predicting HOD, we constructed receiver-operating characteristic curves (ROC) and found that the area under curve (AUC) was (Figure 4). Based on the ROC curve and Youden index, we found that the best FibroScan cut-off value to predict HOD was 60 kpa. At this FibroScan value the sensitivity for detecting HOD was 50% while specificity was 86%, positive predictive value (PPV) was 88% and negative predictive value (NPV) was 47%. Follow-up During the follow-up period, four out of 47 (8.5%) patients with osteoporosis developed fracture within two months of treatment. Sites of fracture were neck of femur, L 3 vertebra, T 11 vertebra and humerus. Patients with osteoporosis (Group C) were treated with monthly ibandronic acid 150 mg orally for six months along with calcium and vitamin D supplements. DEXA scan and other laboratory parameters were repeated in these patients after six months. Sixteen patients (34%) died during the study period and 12 (26%) were lost to follow-up. A total of 19 patients (40%) completed the treatment and were followed up after six months. Serum calcium ( vs , p ¼ 0.002) and vitamin D ( vs , p < 0.001) significantly improved in the treatment group at six months in comparison to baseline. BMD ( vs , p < 0.001) and T score ( vs , p < 0.001) also improved significantly in the treatment group in

5 Bansal et al. 81 Table 4. Etiological comparison among normal BMD (Group A), osteopenia (Group B) and osteoporosis (Group C). Normal BMD (Group A) Osteopenia (Group B) Osteoporosis (Group C) Total Etiology Frequency % Frequency % Frequency % Frequency % ALD % % % % NASH % % % % HBV % % % % Crypto % % % % HCV % % % % Cardiac % % % % Autoimmune % % % % Total % % % % BMD: bone mineral density; ALD: alcoholic liver disease; NASH: non-alcoholic steatohepatitis; HBV: hepatitis B virus; HCV: hepatitis C virus Child A Child B Child C Mean values p Group A Group B Group C Figure 1. Comparison of baseline Child class in normal BMD (Group A), osteopenia (Group B) and osteoporosis (Group C). p ¼ BMD: bone mineral density Group A Group B Group C Group-A vs Group-B P<0.001 Group-A vs Group-C P<0.001 Group-B vs Group-C P=0.001 Figure 3. Comparison of baseline FibroScan value among normal BMD (Group A), osteopenia (Group B) and osteoporosis (Group C). Group A vs Group B p < Group A vs Group C p < Group B vs Group C p ¼ BMD: bone mineral density. Mean values Group A Group B Group C p Figure 2. Comparison of MELD score among normal BMD (Group A), osteopenia (Group B) and osteoporosis (Group C). p ¼ MELD: Model for End-Stage Liver Disease; BMD: bone mineral density. comparison to baseline (Table 5). No adverse events related to ibandronic acid were noted in the treatment group. Discussion This is the largest prospective study from India on the prevalence of HOD in patients with non-cholestatic liver cirrhosis. We studied 215 patients while two other Indian studies enrolled 115 and 72 patients. Our study reported a prevalence of 66% whereas the other studies from India reported a prevalence of 68% 3 and 95%. 4 In Western studies, the prevalence of HOD has been reported to be between 13% and 70%. 1,2 During the follow-up period of one year, four patients developed spontaneous fracture. Other studies

6 82 United European Gastroenterology Journal 4(1) Sensitivity ROC Curve Specificity Figure 4. ROC curve showing utility of FibroScan in detecting HOD. ROC: receiver-operating characteristic; HOD: hepatic osteodystrophy. Table 5. Comparison of demographic and laboratory parameters between treatment group and baseline. Baseline group (n ¼ 19) Mean SD Treatment group (n ¼ 19) Mean SD p value Weight (kg) <0.001 a BMI (kg/m 2 ) <0.001 a Calcium (mg/dl) a Phosphorus(mg/dl) PTH (pg/ml) Vitamin D (ng/ml) <0.001 a BMD <0.001 a T score (g/cm 2 ) ( ) ( ) <0.001 a a Significant p value. BMI: body mass index; PTH: parathyroid hormone; BMD: bone mineral density. have reported a prevalence of fracture between 3% and 18%. 5,6 In our study 8.5% (four of 47) patients with liver cirrhosis who had osteoporosis developed a fracture. Patients with liver cirrhosis should be screened for HOD and treated, and those with osteoporosis should be treated appropriately. The pathogenesis of HOD is multifactorial. These include low lean body mass, inadequate calcium and vitamin D intake, low sunlight exposure, impaired cutaneous synthesis of vitamin D because of skin hyperpigmentation and hypogonadism. 3,7 Patients with autoimmune liver disease or those who are postliver transplantation require immunosuppressive therapy, which may cause further bone mineral loss. 8 Among the predictive factors for HOD, on multivariate logistic regression analysis, FibroScan, BMI, TLC and serum total bilirubin were found to be significantly different in patients with HOD in comparison to those with normal BMD. The relation of FibroScan with BMD value may represent an association with degree of portal hypertension. Difference in BMI is probably related to malnutrition, which leads to HOD. Total serum bilirubin is a part of the LFT, and low TLC may represent a feature of hypersplenism. However, other LFT parameters like albumin or INR were not found to be predictive. All other factors like age, gender distribution, calcium, phosphate, vitamin D, TSH, PTH and gonadal hormones were not significantly different among all three groups. Serum calcium and vitamin D were below normal in the majority of patients among all three groups, and this might be the reason for the lack of difference between the groups. Serum PTH and vitamin D are crucial for bone metabolism; 25 hydroxylation of vitamin D takes place in the liver and this process may be compromised in chronic liver disease, which can result in metabolic bone disorders. However, we did not find a significant correlation between 25-OH D and HOD. This indicates that HOD has a multifactorial pathogenesis beyond vitamin D metabolism. Similar to results for serum calcium and vitamin D, gonadal hormones were low in the vast majority of our patients (90%) but there was no difference among the groups. A likely explanation for these observations is that low vitamin D and gonadal hormone level predispose patients with cirrhosis to HOD. Additional factors like nutrition, as reflected by BMI and weight, ultimately lead to the development of HOD. The relation of severity of liver cirrhosis and HOD has been reported with conflicting results in earlier studies In our study we found that there was no difference in prevalence of HOD with Child score. One probable reason for this may be the very small number of patients with Child class A. Similarly there was no association of HOD with MELD score. This may be explained by the exclusion of patients with renal dysfunction. FibroScan is a non-invasive method for assessing liver stiffness and portal hypertension. No previous study has studied the relationship between FibroScan and BMD. In our study we found that FibroScan value can differentiate between normal BMD with HOD.

7 Bansal et al. 83 When we used 60 kpa as a cut-off point, the specificity for detection of HOD was 86%. The relation between FibroScan and BMD value may represent a relationship with degree of portal hypertension. In our study we didn t find any association of HOD with a particular etiology of liver cirrhosis. Similar results have been shown in previous studies. This is the first study in which bisphosphonates have been used for treatment of osteoporosis in patients with liver cirrhosis. We gave oral bisphosphonate, i.e. ibandronic acid 150 mg, once a month, and after six months of bisphosphonate supplementation all patients showed significant improvement in BMD. There were no adverse events seen in these patients. During the follow-up period of one year, four patients developed spontaneous fracture. All these patients developed fractures within two months of initiating treatment. Larger sample size and long-term follow-up are needed to recommend treatment with ibandronic acid in patients with HOD and cirrhosis. Considering the safety and efficacy of ibandronic acid in this study, it can be used in all cirrhotics with osteoporosis. Limitations of this study were lack of complete information on nutritional status, no separate analysis based on diuretic use, and lack of data about physical activity and sunlight exposure. We also did not analyze any impact of chronic obstructive pulmonary disease (COPD), diabetes, alcohol and smoking. In conclusion, we found a high prevalence (66%) of HOD among Indian patients with non-choleastatic disease. The DEXA scan is a simple and non-invasive method to determine HOD. Screening for HOD should be performed in all liver cirrhosis patients. FibroScan is a modality that can predict HOD in patients with liver cirrhosis with a high degree of specificity. Severity of liver disease (CTP score and MELD score) and etiology of liver cirrhosis did not determine HOD. Ibandronic acid is a safe drug that shows significant improvement in BMD in patients with liver disease along with osteoporosis. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest None declared. References 1. Rouillard S and Lane NE. Hepatic osteodystrophy. Hepatology 2001; 33: Hay JE and Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis 2005; 9: George J, Ganesh HK, Acharya S, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 2009; 15: Choudhary NS, Tomar M, Chawla YK, et al. Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci 2011; 56: Angulo P, Therneau TM, Jorgensen A, et al. Bone disease in patients with primary sclerosing cholangitis: Prevalence, severity and prediction of progression. J Hepatol 1998; 29: Diamond T, Stiel D and Posen S. Osteoporosis in hemochromatosis: Iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989; 110: Goswami R, Gupta N, Goswam D, et al. Prevalence and significance of low 25-hydroxyvitamin D concentrations in healthy subjects in Delhi. Am J Clin Nutr 2000; 72: McDonald AJ, Dunstan CR, Dilworthi P, et al. Bone loss after liver transplantation. Hepatology 1991; 14: Salama AZ, Lotfy AN, El Azizy HM, et al. Evaluation of hepatic osteodystrophy in patients with liver cirrhosis and correlation with severity of liver disease. Arab J Gastroenterol 2007; 8: Cijevevschi C, Mihai C, Zbranca E, et al. Osteoporosis in liver cirrhosis. Rom J Gastroenterol 2005; 14: Chen CC, Wang SS, Jeng FS, et al. Metabolic bone disease of liver cirrhosis: Is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996; 11:

Bone Mineral Density in Thai Patients with Chronic Hepatitis C, before and after Treatment with Pegylated Interferon/Ribavirin Combination ABSTRACT

Bone Mineral Density in Thai Patients with Chronic Hepatitis C, before and after Treatment with Pegylated Interferon/Ribavirin Combination ABSTRACT Original Article 73 before and after Treatment with Pegylated Interferon/Ribavirin Combination Bunchorntavakul C 1 Chotiyaputta W 1 Sriussadaporn S 2 Tanwandee T 1 ABSTRACT Background: Loss of bone mineral

More information

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di

More information

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

STUDY OF CORRELATION OF SEVERITY OF HEPATIC CIRRHOSIS WITH SEVERITY OF BONE CHANGES MEASURED BY BMD (BONE MINERAL DENSITY)

STUDY OF CORRELATION OF SEVERITY OF HEPATIC CIRRHOSIS WITH SEVERITY OF BONE CHANGES MEASURED BY BMD (BONE MINERAL DENSITY) STUDY OF CORRELATION OF SEVERITY OF HEPATIC CIRRHOSIS WITH SEVERITY OF BONE CHANGES MEASURED BY BMD (BONE MINERAL DENSITY) MD. ASHRAFUL ALAM 1, NOORUDDIN AHMED 2, SHAHINUL ALAM 2, MAMUN AL MAHTAB 2 Abstract

More information

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES

SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES YEON SEOK SEO, 1 SOO YOUNG PARK, 2 MOON YOUNG KIM, 3 SANG GYUNE KIM, 4 JUN YONG PARK, 5 HYUNG JOON YIM,

More information

Hepatology for the Nonhepatologist

Hepatology for the Nonhepatologist Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning

More information

King Abdul-Aziz University Hospital (KAUH) is a tertiary

King Abdul-Aziz University Hospital (KAUH) is a tertiary Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors

More information

Primary Sclerosing Cholangitis Medical Management

Primary Sclerosing Cholangitis Medical Management Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive

More information

BMD: A Continuum of Risk WHO Bone Density Criteria

BMD: A Continuum of Risk WHO Bone Density Criteria Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris

More information

Module 1 Introduction of hepatitis

Module 1 Introduction of hepatitis Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand

More information

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,

More information

Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis

Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality

More information

Transient elastography in chronic liver diseases of other etiologies

Transient elastography in chronic liver diseases of other etiologies 4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia

More information

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;

More information

Skeletal Manifestations

Skeletal Manifestations Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of

More information

Study of secondary causes of male osteoporosis

Study of secondary causes of male osteoporosis Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos

More information

Osteoporosis. Overview

Osteoporosis. Overview v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)

More information

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment

More information

Clinician s Guide to Prevention and Treatment of Osteoporosis

Clinician s Guide to Prevention and Treatment of Osteoporosis Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening

More information

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function

More information

Association of vitamin-d levels with the severity of liver disease

Association of vitamin-d levels with the severity of liver disease Original article: Association of vitamin-d levels with the severity of liver disease Jayagowri Karthikeyan, Sujatha Rajaragupathy Department of Biochemistry, PSG Institute of medical sciences and research,

More information

Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine

Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant

More information

Aromatase Inhibitors & Osteoporosis

Aromatase Inhibitors & Osteoporosis Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health

More information

New York State HCV Provider Webinar Series

New York State HCV Provider Webinar Series New York State HCV Provider Webinar Series Overview of Fibrosis-Staging, Child s Pugh, MELD Scores Paul J Gaglio, MD, FACP, AGAF, FAASLD Director: Hepatology Outreach Professor of Medicine (in Surgery)

More information

MEDIC CENTER. Case 2

MEDIC CENTER. Case 2 Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies

More information

Learning Objectives. After attending this presentation, participants will be able to:

Learning Objectives. After attending this presentation, participants will be able to: Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation

More information

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT.

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT. Investigations before OLT, Immunosuppression and rejection, Follow up after OLT andrea.degottardi@insel.ch When is liver transplantation indicated? When is liver transplantation indicated? Frequent: CIRRHOSIS

More information

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient

More information

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death

More information

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Sanjiv Chopra, MD, MACP Professor of Medicine Harvard Medical School Editor In Chief Hepatology Section Up To Date Serum

More information

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 RESEARCH ARTICLE Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 Clinical Outcome and Predictive Factors of Variceal Bleeding in Patients with Hepatocellular Carcinoma in Thailand Jitrapa

More information

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,

More information

Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice

Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice Authors: Mafalda Sousa, Sónia Fernandes, Luísa Proença, Ana Paula Silva, Sónia Leite, Joana Silva, Ana

More information

Correlation between Thyroid Function and Bone Mineral Density in Elderly People

Correlation between Thyroid Function and Bone Mineral Density in Elderly People IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini

More information

Int. J. Pharm. Sci. Rev. Res., 46(1), September - October 2017; Article No. 07, Pages: 37-41

Int. J. Pharm. Sci. Rev. Res., 46(1), September - October 2017; Article No. 07, Pages: 37-41 Research Article Assessment of Clinical Profile and Prescription Pattern of Drugs in Alcoholic Liver Disease and Hepatitis in a Tertiary Care Hospital Christeena James*, Dr.ShirishInamdar, Dr.Bharathi

More information

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008 Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,

More information

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle

More information

Osteoporosis challenges

Osteoporosis challenges Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1

More information

Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis

Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis 168 Original Article Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis Ramin Behroozian 1*, Mehrdad Bayazidchi 1, Javad Rasooli 1 1. Department

More information

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018) PREFERRED AGENTS: (See drug specific NOTES for exceptions.) Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018) https://providers.amerigroup.com For genotype 1, Mavyret and

More information

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,

More information

DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN

DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.

More information

High Prevalence of Vitamin A Deficiency and Vitamin D Deficiency in Patients Evaluated for Liver Transplantation

High Prevalence of Vitamin A Deficiency and Vitamin D Deficiency in Patients Evaluated for Liver Transplantation LIVER TRANSPLANTATION 19:627 633, 2013 ORIGINAL ARTICLE High Prevalence of Vitamin A Deficiency and Vitamin D Deficiency in Patients Evaluated for Liver Transplantation Mukund Venu, Eric Martin, Kia Saeian,

More information

Biomarkers of PSC. Steve Helmke, Ph.D.

Biomarkers of PSC. Steve Helmke, Ph.D. Biomarkers of PSC Steve Helmke, Ph.D. steve.helmke@ucdenver.edu Biomarkers of PSC Currently Used in Clinical Practice Biomarkers Used in Prognostic Models of PSC Wiesner et al, 1989 Age Bilirubin Biopsy

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Thompson AJV; Expert panel representing the Gastroenterological

More information

The Liver for the Nonhepatologist

The Liver for the Nonhepatologist The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Hepatology Director and Medical Director of Liver Transplantation Intermountain Medical Center Salt Lake City, Utah FORMATTED: 05-14-15

More information

Transient elastography in chronic viral liver diseases

Transient elastography in chronic viral liver diseases 4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique

More information

Gastrointestinal bleeding is one of the most important

Gastrointestinal bleeding is one of the most important Prospective Validation of Baveno V Definitions and Criteria for Failure to Control Bleeding in Portal Hypertension Sun Young Ahn, 1 Soo Young Park, 1 Won Young Tak, 1 Yu Rim Lee, 1 Eun Jeong Kang, 1 Jung

More information

Relationship between Decrease in Serum Sodium Level and Bone Mineral Density in Osteoporotic Fracture Patients

Relationship between Decrease in Serum Sodium Level and Bone Mineral Density in Osteoporotic Fracture Patients J Bone Metab 2015;22:9-15 http://dx.doi.org/10.11005/jbm.2015.22.1.9 pissn 2287-6375 eissn 2287-7029 Original Article Relationship between Decrease in Serum Sodium Level and Bone Mineral Density in Osteoporotic

More information

Bone Densitometry Pathway

Bone Densitometry Pathway Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density

More information

Workup of a Solid Liver Lesion

Workup of a Solid Liver Lesion Workup of a Solid Liver Lesion Joseph B. Cofer MD FACS Chief Quality Officer Erlanger Health System Affiliate Professor of Surgery UTHSC-Chattanooga I have no financial or other relationships with any

More information

Predictors of DEXA Use and Guideline Performance for the Detection of Low Bone Mineral Density in Inflammatory Bowel Disease

Predictors of DEXA Use and Guideline Performance for the Detection of Low Bone Mineral Density in Inflammatory Bowel Disease Predictors of DEXA Use and Guideline Performance for the Detection of Low Bone Mineral Density in Inflammatory Bowel Disease Jason Etzel Resident Research Forum Seattle VAMC 6/13/08 Background Increased

More information

Patients must have met all of the following inclusion criteria to be eligible for participation in this study.

Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Supplementary Appendix S1: Detailed inclusion/exclusion criteria Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Inclusion Criteria 1) Willing

More information

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify

More information

Non-Invasive Testing for Liver Fibrosis

Non-Invasive Testing for Liver Fibrosis NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview

More information

The Human Cathelicidin LL37 Peptide has High Plasma Levels in B and C Hepatitis Related to Viral Activity but not to 25-Hydroxyvitamin D Plasma Level

The Human Cathelicidin LL37 Peptide has High Plasma Levels in B and C Hepatitis Related to Viral Activity but not to 25-Hydroxyvitamin D Plasma Level The Human Cathelicidin LL37 Peptide has High Plasma Levels in B and C Hepatitis Related to Viral Activity but not to 25-Hydroxyvitamin D Plasma Level SIMONA ALEXANDRA IACOB 1, EUGENIA PANAITESCU 2, DIANA

More information

Disclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only

Disclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping

More information

Approach to Abnormal Liver Tests

Approach to Abnormal Liver Tests Approach to Abnormal Liver Tests Scott W. Biggins, MD, MAS Assistant Professor Division of Gastroenterology UCSF Scott.Biggins@ucsf.edu (Thanks to Hal Yee, MD) This Morning s Presentation Clinical vignettes

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern

More information

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Hepatocellular Carcinoma: Epidemiology and Screening

Hepatocellular Carcinoma: Epidemiology and Screening Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman

More information

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:

More information

Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis

Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis The Turkish Journal of Pediatrics 2015; 57: 492-497 Original Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis Aysel Ünlüsoy-Aksu 1,

More information

Investigation of Ornithine Carbamoyltransferase as a Biomarker of Liver Cirrhosis

Investigation of Ornithine Carbamoyltransferase as a Biomarker of Liver Cirrhosis ORIGINAL ARTICLE Investigation of Ornithine Carbamoyltransferase as a Biomarker of Liver Cirrhosis Noriko Matsushita 1,2, Etsuko Hashimoto 1, Katsutoshi Tokushige 1, Kazuhisa Kodama 1, Maki Tobari 1, Tomomi

More information

HCV care after cure. This program is supported by educational grants from

HCV care after cure. This program is supported by educational grants from HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico

More information

Bariatric Surgery For Patients With End-Organ Failure

Bariatric Surgery For Patients With End-Organ Failure Bariatric Surgery For Patients With End-Organ Failure Arnold D. Salzberg, M.D. Andrew M. Posselt, M.D., PhD Divisions of Transplant and Minimally Invasive Surgery University of California, San Francisco

More information

Diagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.

Diagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine. Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency

More information

Gamal F. El Naggar (1), Eman A. Alzamarany (2)

Gamal F. El Naggar (1), Eman A. Alzamarany (2) Diagnostic value of Protein Induced by Vitamin K Absence or Antagonist - II (PIVIKA II) in patients with hepatocellular carcinoma (HCC): Comparison with alpha fetoprotein Gamal F. El Naggar (1), Eman A.

More information

The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (10), Page

The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (10), Page The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (10), Page 5391-5395 Study of Vitamin D Level in Cirrhotic HCV Patients before and after Transplantation Amira Ahmed Salem, Wael Ahmed Yousry,

More information

Life After SVR for Cirrhotic HCV

Life After SVR for Cirrhotic HCV Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data

More information

Supplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC

Supplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT

More information

Treatment of HCC in real life-chinese perspective

Treatment of HCC in real life-chinese perspective Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA

More information

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham Making the best use of liver biopsy: clinical perspective Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham Trepanning most efficacious for the relief of maladies so diverse and troublesome

More information

SOLAR-1 (Cohorts A and B)

SOLAR-1 (Cohorts A and B) Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; 149:649-59. Ledipasvir-Sofosbuvir

More information

Sponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)

Sponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.

More information

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:

More information

Prevalence of Comorbidities among HIV-positive patients in Taiwan

Prevalence of Comorbidities among HIV-positive patients in Taiwan Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity

More information

Survival Outcomes Following Liver Transplantation (SOFT) Score: A Novel Method to Predict Patient Survival Following Liver Transplantation

Survival Outcomes Following Liver Transplantation (SOFT) Score: A Novel Method to Predict Patient Survival Following Liver Transplantation American Journal of Transplantation 2008; 8: 2537 2546 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant

More information

SOLAR-1 (Cohorts A and B)

SOLAR-1 (Cohorts A and B) Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; [Epub ahead of print]

More information

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014 HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research

More information

Practical Management Of Osteoporosis

Practical Management Of Osteoporosis Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda

More information

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate

More information

UMHS-PUHSC JOINT INSTITUTE

UMHS-PUHSC JOINT INSTITUTE Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,

More information

Applied Health Economics and Health Policy

Applied Health Economics and Health Policy Applied Health Economics and Health Policy Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal Elamin H. Elbasha, Jagpreet Chhatwal,

More information

Approach to a patient with hypercalcemia

Approach to a patient with hypercalcemia Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical

More information

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),

More information

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated

More information

B C Outlines. Child-Pugh scores

B C Outlines. Child-Pugh scores B C 2016-12-09 Outlines Child-Pugh scores CT MRI Fibroscan / ARFI Histologic Scoring Systems for Fibrosis Fibrosis METAVIR Ishak None 0 0 Portal fibrosis (some) 1 1 Portal fibrosis (most) 1 2 Bridging

More information

Chronic liver failure Assessment for liver transplantation

Chronic liver failure Assessment for liver transplantation Chronic liver failure Assessment for liver transplantation Liver Transplantation Dealing with the organ shortage Timing of listing must reflect length on waiting list Ethical issues Justice, equity, utility

More information

Screening for Portal Hypertension in Cirrhosis

Screening for Portal Hypertension in Cirrhosis Screening for Portal Hypertension in Cirrhosis MASSIMO PINZANI, MD, PhD, FRCP Sheila Sherlock Chair of Hepatology UCL Institute for Liver and Digestive Health Royal Free Hospital, London, UK m.pinzani@ucl.ac.uk

More information

Screening cardiac patients for advanced liver disease

Screening cardiac patients for advanced liver disease HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD

More information

Research Article Incidence of Fractures after Cardiac and Lung Transplantation: A Single Center Experience

Research Article Incidence of Fractures after Cardiac and Lung Transplantation: A Single Center Experience Osteoporosis, Article ID 573041, 8 pages http://dx.doi.org/10.1155/2014/573041 Research Article Incidence of Fractures after Cardiac and Lung Transplantation: A Single Center Experience Aileen Hariman,

More information

The Future is Here Now!

The Future is Here Now! HCV Treatment: Assessing the Patient Prior to Treatment. How Will This Change in the Future? JORGE L. HERRERA M.D., FACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The Future is Here Now!

More information